Comparative Pharmacology
Head-to-head clinical analysis: CEFADYL versus CEFTAZIDIME IN DEXTROSE CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFADYL versus CEFTAZIDIME IN DEXTROSE CONTAINER.
CEFADYL vs CEFTAZIDIME IN DEXTROSE CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
1-2 g IV/IM every 6 hours for moderate to severe infections; maximum 12 g/day.
1-2 g intravenously every 8 hours.
None Documented
None Documented
30-60 minutes in adults with normal renal function; prolonged to 10-20 hours in end-stage renal disease. Requires dose adjustment for CrCl <30 mL/min.
1.9 hours (normal renal function); prolonged to 22-30 hours in ESRD
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: minimal.
Renal: 80-90% unchanged drug via glomerular filtration; biliary: <1%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic